These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 25229923)
1. Dalbavancin or oritavancin for skin infections. Núñez-Núñez M; Rodríguez-Baño J N Engl J Med; 2014 Sep; 371(12):1160. PubMed ID: 25229923 [No Abstract] [Full Text] [Related]
2. Dalbavancin or oritavancin for skin infections. Corey GR; Jiang H; Moeck G N Engl J Med; 2014 Sep; 371(12):1162-3. PubMed ID: 25243251 [No Abstract] [Full Text] [Related]
3. Dalbavancin or oritavancin for skin infections. Baang J; Fisher S N Engl J Med; 2014 Sep; 371(12):1160-1. PubMed ID: 25229924 [No Abstract] [Full Text] [Related]
4. Dalbavancin or oritavancin for skin infections. Boucher HW; Talbot GH; Dunne MW N Engl J Med; 2014 Sep; 371(12):1161-2. PubMed ID: 25229922 [No Abstract] [Full Text] [Related]
5. Dalbavancin or oritavancin for skin infections. Cormican M N Engl J Med; 2014 Sep; 371(12):1161. PubMed ID: 25229925 [No Abstract] [Full Text] [Related]
6. Pharmacology and the treatment of complicated skin and skin-structure infections. Chambers HF N Engl J Med; 2014 Jun; 370(23):2238-9. PubMed ID: 24897088 [No Abstract] [Full Text] [Related]
7. Weekly dalbavancin was noninferior to daily vancomycin for acute bacterial skin infection in adults. Zervou FN; Zacharioudakis IM; Mylonakis E Ann Intern Med; 2014 Oct; 161(8):JC9. PubMed ID: 25329226 [No Abstract] [Full Text] [Related]
8. Dalbavancin and Oritavancin: An Innovative Approach to the Treatment of Gram-Positive Infections. Roberts KD; Sulaiman RM; Rybak MJ Pharmacotherapy; 2015 Oct; 35(10):935-48. PubMed ID: 26497480 [TBL] [Abstract][Full Text] [Related]
10. Once-weekly dalbavancin versus daily conventional therapy for skin infection. Boucher HW; Wilcox M; Talbot GH; Puttagunta S; Das AF; Dunne MW N Engl J Med; 2014 Jun; 370(23):2169-79. PubMed ID: 24897082 [TBL] [Abstract][Full Text] [Related]
11. Newer glycopeptide antibiotics for treatment of complicated skin and soft tissue infections: systematic review, network meta-analysis and cost analysis. Agarwal R; Bartsch SM; Kelly BJ; Prewitt M; Liu Y; Chen Y; Umscheid CA Clin Microbiol Infect; 2018 Apr; 24(4):361-368. PubMed ID: 28882727 [TBL] [Abstract][Full Text] [Related]
12. Role or oritavancin and dalbavancin in acute bacterial skin and skin structure infections and other potential indications. Bassetti M; Labate L; Vena A; Giacobbe DR Curr Opin Infect Dis; 2021 Apr; 34(2):96-108. PubMed ID: 33405480 [TBL] [Abstract][Full Text] [Related]
13. A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin. Guskey MT; Tsuji BT Pharmacotherapy; 2010 Jan; 30(1):80-94. PubMed ID: 20030476 [TBL] [Abstract][Full Text] [Related]
16. Comparative In Vitro Activities of Oritavancin, Dalbavancin, and Vancomycin against Methicillin-Resistant Staphylococcus aureus Isolates in a Nondividing State. Belley A; Lalonde Seguin D; Arhin F; Moeck G Antimicrob Agents Chemother; 2016 Jul; 60(7):4342-5. PubMed ID: 27067327 [TBL] [Abstract][Full Text] [Related]
17. New Gram Positive Agents to Treat Acute Bacterial Skin and Skin Structure Infections. Li R; Nailor MD Conn Med; 2016 Mar; 80(3):175-80. PubMed ID: 27169303 [TBL] [Abstract][Full Text] [Related]
18. New antibiotics in the management of acute bacterial skin and skin structure infections. Gleghorn K; Grimshaw E; Kelly EK Skin Therapy Lett; 2015; 20(5):7-9. PubMed ID: 26382907 [TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic drug evaluation of dalbavancin for the treatment of skin infections. Galluzzo M; D'Adamio S; Bianchi L; Talamonti M Expert Opin Drug Metab Toxicol; 2018 Feb; 14(2):197-206. PubMed ID: 29258361 [TBL] [Abstract][Full Text] [Related]
20. Beyond Vancomycin: The Tail of the Lipoglycopeptides. Klinker KP; Borgert SJ Clin Ther; 2015 Dec; 37(12):2619-36. PubMed ID: 26658277 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]